Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY 4.0Medicine

Association between prior HBV vaccine responsiveness and booster-induced anti-SARS-CoV-2 spike antibody titers following the third BNT162b2 dose in Japanese healthcare workers: A prospective observational study

10 affiliations
  1. 1Department of General Medicine, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan
  2. 2Department of Obstetrics and Gynecology, Kochi Health Sciences Center, Kochi, Japan
  3. 3Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan
  4. 4Department of Nursing, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan
  5. 5Central Clinical Laboratory, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
  6. 6Department of Anesthesiology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
  7. 7Infection Control Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan
  8. 8Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
  9. 9Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
  10. 10Hirakata City Hospital, Hirakata, Osaka, Japan.

Abstract

Inter-individual variability in vaccine-induced humoral responses has been reported even among generally healthy individuals. In our previous study, healthcare workers with poor hepatitis B virus (HBV) vaccine responsiveness were more likely to show a low anti-SARS-CoV-2 spike antibody response after the first BNT162b2 dose. This study examined whether such differences persisted after a third BNT162b2 dose. This was an extended follow-up study of a previously reported prospective observational cohort of Japanese healthcare workers. The primary outcome was the quantitative anti-SARS-CoV-2 spike antibody titer measured 12 weeks after the third BNT162b2 dose. Participants were classified as normal HBV vaccine responders, weak responders, or non-responders. Comparisons across HBV response groups were performed using the Kruskal–Wallis test and multivariable linear regression adjusted for age and sex. A low antibody-response analysis (<15 U/mL) after the first dose was evaluated as a secondary analysis. Among 741 participants with antibody measurements 12 weeks after the third dose, 486 were normal HBV vaccine responders, 229 were weak responders, and 26 were non-responders. The median anti-SARS-CoV-2 spike antibody titer was 891,900 U/mL. Titers did not differ significantly across HBV response groups in the unadjusted analysis (P = .3718) or after adjustment for age and sex (global P = .3971). Compared with normal responders, the adjusted geometric mean ratio was 0.94 (95% CI, 0.83–1.07) for weak responders and 0.83 (95% CI, 0.60–1.15) for non-responders. By contrast, after the first dose, HBV vaccine non-responders had an increased risk of a low antibody response (<15 U/mL) compared with normal responders (adjusted RR, 1.85; 95% CI, 1.10–3.13). Differences in early anti-SARS-CoV-2 spike antibody responses associated with prior HBV vaccine responsiveness were no longer statistically apparent 12 weeks after the third BNT162b2 dose. These findings suggest convergence of measured humoral antibody responses after booster vaccination, although they do not establish that the underlying biological mechanisms of vaccine hyporesponsiveness were eliminated.

Related

  1. Impact of Chronic Heart Failure on Vascular Responsiveness: A Prospective Observational In Vivo and Ex Vivo Study in Patients Undergoing Cardiac Surgery
    Olga Papazisi, Marieke E. van Vessem, Saskia L. M. A. Beeres +10
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossrefEurope PMC
  2. Incidence and Progression of Acute Kidney Injury Following Head and Neck Surgeries for COVID-19-Associated Mucormycosis: A Prospective Observational Study
    Kalyani M Rapeti, Habib Md R Karim, Chinmaya K Panda +3
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Ultrasonographic changes following pyeloplasty in children with ureteropelvic junction obstruction: a prospective observational before-after cohort study
    Farnoush Izadfar, Reza Abbasioun, Ahmad Mohammadipour +5
    Annals of medicine and surgery (2012)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Longitudinal Changes in Anxiety and Depression Following First Implantable Cardioverter-Defibrillator Implantation: A Prospective Observational Study
    Vincenzo Sgaramella, Antonio Gianluca Robles, Domenico Rosario Riccardo Chieppa +7
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Association between neutrophil percentage-to-albumin ratio and all-cause mortality in stroke survivors stratified by triglyceride-glucose index : A prospective observational study based on the NHANES database from 1999 to 2018
    Ning Liu, Zhongzhou Su, Sheng Zhang
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{misawa2026association,
  title = {{Association between prior HBV vaccine responsiveness and booster-induced anti-SARS-CoV-2 spike antibody titers following the third BNT162b2 dose in Japanese healthcare workers: A prospective observational study}},
  author = {Miwa Misawa and Momoko Iwamoto and Tomoyuki Yamada and Fumiko Kawanishi and Masami Nishihara and Akira Asai and Yusuke Kusaka and Taku Ogawa and Takashi Nakano and Akira Ukimura and Tomio Suzuki},
  journal = {Medicine},
  year = {2026},
  month = nov,
  doi = {10.1097/md.0000000000051417},
  url = {https://doi.org/10.1097/md.0000000000051417},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Association between prior HBV vaccine responsiveness and booster-induced anti-SARS-CoV-2 spike antibody titers following the third BNT162b2 dose in Japanese healthcare workers: A prospective observational study
AU  - Miwa Misawa
AU  - Momoko Iwamoto
AU  - Tomoyuki Yamada
AU  - Fumiko Kawanishi
AU  - Masami Nishihara
AU  - Akira Asai
AU  - Yusuke Kusaka
AU  - Taku Ogawa
AU  - Takashi Nakano
AU  - Akira Ukimura
AU  - Tomio Suzuki
PY  - 2026
DA  - 2026/11/06
JO  - Medicine
DO  - 10.1097/md.0000000000051417
UR  - https://doi.org/10.1097/md.0000000000051417
AB  - Inter-individual variability in vaccine-induced humoral responses has been reported even among generally healthy individuals. In our previous study, healthcare workers with poor hepatitis B virus (HBV) vaccine responsiveness were more likely to show a low anti-SARS-CoV-2 spike antibody response after the first BNT162b2 dose. This study examined whether such differences persisted after a third BNT162b2 dose. This was an extended follow-up study of a previously reported prospective observational cohort of Japanese healthcare workers. The primary outcome was the quantitative anti-SARS-CoV-2 spike antibody titer measured 12 weeks after the third BNT162b2 dose. Participants were classified as normal HBV vaccine responders, weak responders, or non-responders. Comparisons across HBV response groups were performed using the Kruskal–Wallis test and multivariable linear regression adjusted for age and sex. A low antibody-response analysis (<15 U/mL) after the first dose was evaluated as a secondary analysis. Among 741 participants with antibody measurements 12 weeks after the third dose, 486 were normal HBV vaccine responders, 229 were weak responders, and 26 were non-responders. The median anti-SARS-CoV-2 spike antibody titer was 891,900 U/mL. Titers did not differ significantly across HBV response groups in the unadjusted analysis (P = .3718) or after adjustment for age and sex (global P = .3971). Compared with normal responders, the adjusted geometric mean ratio was 0.94 (95% CI, 0.83–1.07) for weak responders and 0.83 (95% CI, 0.60–1.15) for non-responders. By contrast, after the first dose, HBV vaccine non-responders had an increased risk of a low antibody response (<15 U/mL) compared with normal responders (adjusted RR, 1.85; 95% CI, 1.10–3.13). Differences in early anti-SARS-CoV-2 spike antibody responses associated with prior HBV vaccine responsiveness were no longer statistically apparent 12 weeks after the third BNT162b2 dose. These findings suggest convergence of measured humoral antibody responses after booster vaccination, although they do not establish that the underlying biological mechanisms of vaccine hyporesponsiveness were eliminated.
SN  - 0025-7974
SN  - 1536-5964
ER  -